期刊文献+

造血干细胞移植预处理对血小板膜糖蛋白表达和聚集功能的影响

Investigation of Platelet Membrane Glycoprotein Expression and Platelet Aggregation Function During the Conditional Treatment in Patients Undergoing Hematopoietic Stem Cell Transplantation
原文传递
导出
摘要 目的研究造血干细胞移植预处理对血小板膜糖蛋白表达和血小板聚集功能的影响。方法应用血小板聚集仪检测29例造血干细胞移植患者预处理前后ADP诱导的血小板聚集功能变化,同时用流式细胞仪观察血小板膜糖蛋白(GP)Ⅰb、Ⅱb、Ⅲa和CD62P表达水平的改变。20名健康人为正常对照。结果移植患者预处理前血小板对ADP的最大聚集率为(56.73±20.38)%,和正常人的(57.66±12)%相比,无明显差异(P>0.05);预处理后血小板对ADP的最大聚集率降至(31.38±25.81)%,与预处理前比较,差异显著(P<0.01)。GPⅡb、GPⅢa与CD62P在预处理后较正常组及预处理前明显升高(P<0.05),GPⅠb变化不明显。预处理过程中血凝常规无明显改变。结论造血干细胞移植预处理会引起血小板的活化,导致血小板聚集功能与血小板膜GP的改变,这可能是导致出血或血栓等并发症的原因之一。 Objective To investigate the effects of conditioning treatment for hematopoietic stem cell transplantation (HSCT) on platelet membrane glycoprotein (GP) expression and platelet aggregation function. Methods Platelet aggregation induced by ADP was tested in 29 patients undergoing HSCT in the course of conditioning treatment. The expressing of GPIb ,GPHb, GPma and CD62P before and after conditioning treatment for HSCT were detected using a flow cytometer. Tweenty healthy volunteers were selected as the control subjects. Results There was no significant difference in the level of the maximal platelet aggregation induced by ADP between the patients before conditioning treatment[ (56.73±20. 38) % ] and the normal subjects [ ( 57.66 ±12) % ] ( P 〉 0.05 ). While the maximal platelet aggregation rate after conditioning treatment [ (31.38±25.81 ) % ] induced by ADP was significantly lower (P 〈0.05). The expressions of platelet membrane GPIIb, Ilia and CD62P post conditional treatment were higher than those in the control group or pre-conditional treatment, GPIb didn't changed at the same time. There was no alteration of coagulation parameters after conditioning treatment. Conclusion The conditioning treatment for HSCT induces the activation of platelet, leading to the alterations of platelet aggregation and platelet membrane glycoprotein expression, which may be one of the pathogenetic reasons for the complications of bleeding or thrombosis.
出处 《苏州大学学报(医学版)》 CAS 北大核心 2009年第6期1136-1139,共4页 Suzhou University Journal of Medical Science
关键词 造血干细胞移植 血小板膜糖蛋白 血小板 聚集 hematopoietic stem cell transplantion platelet glycoprotein platelet aggregation
  • 相关文献

参考文献6

  • 1张桂新,冯四洲.急性髓系白血病异基因造血干细胞移植清髓性预处理方案研究进展[J].国际输血及血液学杂志,2006,29(4):341-345. 被引量:2
  • 2Pihusch R, Hohnberg B, Salat C, et al. Platelet flow cytometric findings in patients undergoing conditioning therapy for allogeneic hematopoietic stem cell transplantation [ J ]. Ann Hematol, 2002,81 (8) :454 -461.
  • 3Cywes R, Mullen J B, Stratis MA, et al. Prediction of the outcome of transplantation in man by platelet adherence in donor liver allografts: evidence of the importance of prepreservation injury[J]. Transplantation, 1993,56(2) :316 - 323.
  • 4汤立,侯建全,戴兰,沈文红,陈凤玲.血小板活化指标CD62P、CD63和PAC-1在血透患者自身动静脉内瘘反复失功中的意义[J].苏州大学学报(医学版),2008,28(5):785-788. 被引量:8
  • 5Gerber DE, Segal JB, Levy MY, et al. The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention [J]. Blood, 2008,112(3) :504 -510.
  • 6Nevo S, Fuller AK, Hartley E,et al. Acute bleeding complications in patients after hematopoietic stem cell transplantation with prophylactic platelet transfusion triggers of 10×10^9 and 20×10^9 per L[J]. Transfusion, 2007,47 (5) :801 -812.

二级参考文献32

  • 1Hakim R, Himmelfarb J. Hemodialysis access failure: a call to action[J]. Kidney Int 1998, 54(7):1029-1040.
  • 2Zibari GB, Rohr MS, Landereneau MD, et al. Complication from permanent hemodialysis access[J]. Surgery 1998, 104 (3):681-686.
  • 3Peter K, Straub A, Kohler B, et al. Platelet activation as a potential mechanism of GP Ⅱ b/Ⅲa inhibitor-induced thrombocytopenia[J]. Am J Cardiol, 1999,84 (5): 519-521.
  • 4Chuang YC, Chen JB, Yang LC, et al. Significance of platelet activation in vascular access survival of haemodialysis patients [J]. Nephrology Dialysis Transplantation 2003,18(5):947-954.
  • 5Blaise D, Maraninchi D, Archimbaud E, et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-cytoxan vs cytoxantotal body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse. Blood, 1992,79(10) : 2578-2582.
  • 6Ringden O, Ruutu T, Remberger M,et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood,1994,83(9) :2723-2730.
  • 7Ringden O, Labopin M, Tura S, et al. A comparison of busulpban vs total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bonemarrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol,1996, 93(3):637-645.
  • 8Litzow MR, Perez WS, Klein JP,et al. Comparison of outcome following allogeneic bone transplantation with cyclophosphamide-total body irradiation busulphancyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol, 2002,119 (4) : 1115-1124.
  • 9Michel G, Gluckman E, Esperou-Bourdeau H, et al. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation-a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol,1994, 12(6):1217-1222.
  • 10Blaise D, Maraninchi D, Michallet M,et al. Long-term follow up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission.Blood, 2001,97 ( 11 ) : 3669-3671.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部